ERBB2 and breast carcinoma: Further studies with novel anti-HER-2-targeted therapies, such as pertuzumab, TDM-1, and Neratinib, continue to explore the value of multiple lines of anti-HER2 therapies in this subpopulation of breast cancer patients (Baselga et al, 2010; Burstein et al, 2010; Burris et al, 2011).